First FDA clearance for TMS in depression; could be effective in coma
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for the first transcranial magnetic stimulation (TMS) device for depression, Neuronetics' Neurostar. The specific indication is for the treatment of adults with major depressive disorder who have not responded to antidepressant drugs.
You may also be interested in...
US FDA used its de novo review pathway to approve Brainsway Ltd.’s Brainsway Deep Transcranial Magnetic Stimulation System to treat obsessive compulsive disorder.
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.